Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cenix BioScience Joins EU FP7 Consortium

Published: Wednesday, March 30, 2011
Last Updated: Wednesday, March 30, 2011
Bookmark and Share
Consortium focused on improving the in vivo use of siRNA technology in the area of respiratory and inflammatory diseases.

Cenix BioScience GmbH, has announced that it has joined an EU-funded consortium focused on improving the in vivo use of siRNA technology in the area of respiratory and inflammatory diseases.

The consortium, named TACIT and funded by the EU FP7’s Marie Curie Actions program, was originally started in August 2009 by the groups of Dr. Evangelos Andreakos (Biomedical Research Foundation, Academy of Athens, Athens, Greece), Dr. Cristos Tsatsanis (University of Crete, Heraklion, Greece) and Germany-based Novosom AG.

Following the successful 2010 sale by Novosom of its key liposomal carrier technology and its subsequent exit from the consortium, Cenix was invited to replace Novosom for the remainder of the funding period, lasting until mid-2013.

The consortium’s updated project, recently approved by the EU, will focus on testing a variety of novel siRNA delivery solutions, including embodiments of proprietary Cenix DARE™ technology, that together promise innovative and groundbreaking new ways of addressing this field’s top challenge for both research and therapeutic applications.

The Marie Curie funding primarily supports the new recruitment and exchanges of scientific personnel by and between consortium members within the EU.

Complementing the world-class expertise offered by the groups of Drs. Andreakos and Tsatsanis using in vivo models in these disease areas, Cenix will apply both cell-based and in vivo RNAi capabilities built up at its Dresden-based operations.

In particular, Cenix will leverage its state-of-the-art high-content assay capabilities using multi-parametric microscopy readouts enhanced by industry-leading Definiens Developer XD image analysis tools, to analyze the intra-tissue and intra-cellular fate of siRNAs and their associated delivery vehicles.

This effort adds further breadth to the in vivo RNAi program started by Cenix in 2008, which also includes CNS-focused R&D undertaken by the new Belgian Cenix subsidiary announced recently. Together, these complementary initiatives are diversifying the company's activities beyond the cell-based RNAi services that established it as a global leader in the RNAi research field over the past 11 years.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cenix, Metanomics Partner to Develop Metabolomic Biomarkers
Companies sign a research framework agreement focused on comprehensive metabolite profiling services and the development of metabolomic biomarkers.
Friday, September 05, 2014
Cenix BioScience Signs Research Service Agreement with Bayer Pharma AG
Company will undertake a target discovery project for an undisclosed disease indication.
Tuesday, May 06, 2014
Cenix BioScience Joins EU FP7 Consortium for Discovery of miRNA Medicines
Company has joined an EU-funded consortium focused on the discovery of microRNA medicines in the area of cardiac and inflammatory metabolic diseases.
Wednesday, August 14, 2013
Cenix BioScience Expands Operations to U.S.
Company establishes new subsidiary named Cenix BioScience USA in Minnesota.
Friday, March 02, 2012
Cenix signs RNAi research agreement with SYGNIS
Cenix BioScience GmbH, announced it has signed a research agreement with SYGNIS Bioscience GmbH & Co. KG, a pharmaceutical company dedicated to developing innovative therapies for the treatment of disorders of the central nervous system.
Thursday, November 17, 2011
Cenix BioScience Signs Collaboration and Technology License Agreement for In Vivo siRNA Delivery
Collaboration and Technology License Agreement to improve the in vivo applicability of siRNA-based experimentation, focusing on the further co-development of DARE™.
Thursday, May 05, 2011
Cenix BioScience Grows, Establishing New R&D Subsidiary in Flanders, Belgium
The new company accelerates the development of the company’s R&D capabilities in key growth areas including CNS-focused drug discovery and in vivo RNAi.
Saturday, January 15, 2011
Cenix BioScience Expands Relationship with AstraZeneca, Signing Multi-Project Research Agreement
The new agreement calls for Cenix to complete three major projects applying same platform for RNAi-based research.
Friday, June 26, 2009
Cenix BioScience Signs Multi-Project Research Agreement with AstraZeneca
The agreement expands relationship beyond its initial oncology focus, to now include respiratory and inflammation-related indications.
Tuesday, June 16, 2009
InteRNA Technologies and Cenix BioScience Ink Research Agreement for miRNA Drug Discovery
The research agreement comprises functional screens in human cell lines using InteRNA’s proprietary library of miRNAs.
Tuesday, November 18, 2008
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Making Personalized Medicine a Reality
Groundbreaking technique developed at McMaster University is helping to pave the way for advances in personalized medicine.
Accelerating the Detection of Foodborne Bacterial Outbreaks
The speed of diagnosis of foodborne bacterial outbreaks could be improved by a new technique developed by researchers at the Georgia Institute of Technology.
Scientists Identify Unique Genomic Features in Testicular Cancer
The findings may shed light on factors in other cancers that influence their sensitivity to chemotherapy.
Top 10 Life Science Innovations of 2016
2016 has seen the release of some truly innovative products. To help you digest these developments, The Scientist have listed their top picks for the year.
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
Possible Treatment for Rare Vascular Disease
Researchers manage to reverse hereditary haemorrhagic telangiectasia in mice, if successful in humans it could lead to improved treatment for the disease.
Sweet Tooth Science - Chocolate Antioxidants
Researchers develop a faster and cheaper method to test for antioxidants in chocolate.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!